2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3096

Interferon-Gamma (IFNg) in Macrophage Activation Syndrome (MAS): CXCL9 Levels As a Biomarker for IFNg Production in MAS
Abstract Number: 1098

Interleukin-1 Reciprocally Regulates Interferon-Gamma Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) and Interleukin-6 in Human Synovial Fibroblasts
Abstract Number: 2207

Interleukin-32Î³ Exhibited Protective Effects on Osteoporosis
Abstract Number: 287

Interleukin-35 in Idiopathic Inflammatory Myopathies
Abstract Number: 1925

Interleukin-35 Is Upregulated in Systemic Sclerosis and Its Serum Levels Are Increased in Early Disease
Abstract Number: 1176

Interleukin-37 Prevents New-Onset Joint Inflammation but Does Not Inhibit Existing Experimental Arthritis
Abstract Number: 1189

Internal Medicine Subspecialty Fellows’ Attitudes Towards Teaching and Learning How to Teach: A Needs Assessment
Abstract Number: 1961

Interobserver Agreement on Ultrasonographic and Magnetic Resonance Angiography Findings in Patients with Large Vessel Vasculitis
Abstract Number: 2968

Interrater Reliability of Nailfold Capillaroscopy in Systemic Sclerosis Using Widefield Microscopy
Abstract Number: 1983

Interspinous Bursitis Evaluation By Ultrasound Is Very Useful for Diagnosis of Polymyalgia Rheumatica
Abstract Number: 2375

Interstitial Lung Disease in Patients with Anti-PM-Scl Antibody
Abstract Number: 1025

Interstitial Lung Disease in Sting-Associated Vasculopathy with Onset in Infancy (SAVI): Genotype-Phenotype Correlation
Abstract Number: 897

Intra-Articular Corticosteroids Are Safe and Have No Major Effect on Structural Progression of Synovitic Knee OA: A 2-Year Randomized Controlled Trial of 3-Monthly Triamcinolone Hexacetonide
Abstract Number: 2115

Intra-Operative Synovitis Predicts Worse Pain and Function 2 Years after Total Knee Arthroplasty for Osteoarthritis
Abstract Number: 2895

Intraarticular Sacroiliac Corticosteroid Injections in Ankylosing Spondylitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].